Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Penoctonium SCHEMBL2734618 | 0.99 | DNM1 (0.41) | TSHRDNM1EPHX1EPHX2 | |
| Dipenine SCHEMBL29385249 | 0.87 | CHRM1 (0.44) | TSHREPHX1 | |
| Dipenine SCHEMBL25069 | 0.86 | CHRM1 (0.43) | TSHREPHX1 | |
| Hydrochloric Acid SCHEMBL10492769 | 0.71 | DGKA (0.62) | TSHRDNM1 | |
| SCHEMBL7654322 | 0.70 | TSHR (0.57) | TSHREPHX1EPHX2 | |
| SCHEMBL7658530 | 0.70 | TSHR (0.57) | TSHREPHX1EPHX2 | |
| SCHEMBL7662341 | 0.70 | TSHR (0.57) | TSHREPHX1EPHX2 | |
| SCHEMBL11099177 | 0.70 | TSHR (0.59) | TSHRDNM1 | |
| SCHEMBL2744210 | 0.70 | TSHR (0.65) | TSHRDNM1 | |
| Hydrochloric Acid SCHEMBL28573850 | 0.70 | TSHR (0.65) | TSHRDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017879-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF | Bio Logic Crop Science S.L. (ES) | 2025-01-16 | — | — | US | disclosed |
| EP-4427745-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF | Bio Logic Crop Science, S.L. (ES) | 2024-09-11 | — | — | EP | disclosed |
| US-11766364-B2 | Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents | ETHICON, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11452641-B2 | Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents | ETHICON, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220296423-A1 | Wound Closure Systems for Reducing Surgical Site Infections Comprising Incision Drapes Filled with Releasable Antimicrobial Agents | ETHICON, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220296422-A1 | Wound Closure Systems for Reducing Surgical Site Infections Comprising Incision Drapes Filled with Releasable Antimicrobial Agents | ETHICON, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| EP-3989865-A1 | WOUND CLOSURE SYSTEMS FOR REDUCING SURGICAL SITE INFECTIONS COMPRISING INCISION DRAPES FILLED WITH RELEASABLE ANTIMICROBIAL AGENTS | Ethicon, Inc (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017879-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF | SARS1, ACE2, PHOSPHO1 | TSHR 2576/4885DNM1 899/4885EPHX1 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.